Ritu Baral
Stock Analyst at TD Cowen
(2.48)
# 2,482
Out of 5,044 analysts
37
Total ratings
46.67%
Success rate
3.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Downgrades: Hold | $78 → $74 | $69.93 | +5.82% | 2 | Oct 29, 2025 | |
| INSM Insmed | Maintains: Buy | $154 → $193 | $165.29 | +16.76% | 4 | Oct 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $39 | $22.62 | +72.41% | 2 | Sep 11, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $429.18 | +29.08% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $54.00 | +40.74% | 1 | Aug 4, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $73.50 | -40.14% | 1 | Feb 5, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.38 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.29 | - | 2 | Nov 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $475.91 | -22.04% | 4 | Oct 21, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $8.24 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $24.22 | +622.54% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $124.51 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.62 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.00 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.96 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.96 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.59 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.78 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.62 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $755.00 | - | 2 | Jan 12, 2018 |
Avidity Biosciences
Oct 29, 2025
Downgrades: Hold
Price Target: $78 → $74
Current: $69.93
Upside: +5.82%
Insmed
Oct 2, 2025
Maintains: Buy
Price Target: $154 → $193
Current: $165.29
Upside: +16.76%
ACADIA Pharmaceuticals
Sep 11, 2025
Maintains: Buy
Price Target: $35 → $39
Current: $22.62
Upside: +72.41%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $429.18
Upside: +29.08%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $54.00
Upside: +40.74%
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $73.50
Upside: -40.14%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.38
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.29
Upside: -
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $475.91
Upside: -22.04%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.24
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $24.22
Upside: +622.54%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $124.51
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.62
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.00
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.96
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $29.96
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.59
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.78
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $755.00
Upside: -